Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emilie M J van Brummelen

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Clinical and Translational Science|December 27, 2021
A phase I, randomized, double-blind, placebo-controlled, single- and multiple dose escalation study evaluating the safety, pharmacokinetics and pharmacodynamics of VX-128, a highly selective Na<sub>v</sub> 1.8 inhibitor, in healthy adultsHemme J Hijma, Emilie M J van Brummelen, Pieter S Siebenga, et al.
The Oncologist|June 4, 2017
<i>BRAF</i> Mutations as Predictive Biomarker for Response to Anti-EGFR Monoclonal AntibodiesEmilie M J van Brummelen, Anthonius de Boer, Jos H Beijnen, et al.
Plos One|December 7, 2021
Touchscreen-based finger tapping: Repeatability and configuration effects on tapping performanceSoma Makai-Bölöni, Eva Thijssen, Emilie M J van Brummelen, et al.
The Oncologist|July 22, 2016
Antidrug Antibody Formation in Oncology: Clinical Relevance and ChallengesEmilie M J van Brummelen, Willeke Ros, Gertjan Wolbink, et al.
Parkinsonism & Related Disorders|April 2, 2022
Safety and pharmacokinetics of multiple dosing with inhalable apomorphine (AZ-009), and its efficacy in a randomized crossover study in Parkinson's disease patientsEva Thijssen, Jonas M den Heijer, David Puibert, et al.
Frontiers in Oncology|September 15, 2022
Integration of healthy volunteers in early phase clinical trials with immuno-oncological compoundsIgor Radanovic, Naomi Klarenbeek, Robert Rissmann, et al.
Human Vaccines & Immunotherapeutics|November 2, 2019
Prevalent levels of RSV serum neutralizing antibodies in healthy adults outside the RSV-seasonJohan L Van Der Plas, Pauline Verdijk, Emilie M J Van Brummelen, et al.
British Journal of Clinical Pharmacology|September 24, 2021
Healthy volunteers in first-in-human oncology drug development for small moleculesBegoña de Las Heras, Dalila Bouyoucef-Cherchalli, Lesley Reeve, et al.
Journal of Clinical Movement Disorders|April 14, 2020
Quantification of tremor using consumer product accelerometry is feasible in patients with essential tremor and Parkinson's disease: a comparative studyEmilie M J van Brummelen, Dimitrios Ziagkos, Wadim M I de Boon, et al.
Vaccine|July 29, 2020
First-in-human administration of a live-attenuated RSV vaccine lacking the G-protein assessing safety, tolerability, shedding and immunogenicity: a randomized controlled trialPauline Verdijk, Johan L van der Plas, Emilie M J van Brummelen, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Clinical and Translational Science|December 27, 2021
A phase I, randomized, double-blind, placebo-controlled, single- and multiple dose escalation study evaluating the safety, pharmacokinetics and pharmacodynamics of VX-128, a highly selective Na<sub>v</sub> 1.8 inhibitor, in healthy adultsHemme J Hijma, Emilie M J van Brummelen, Pieter S Siebenga, et al.
The Oncologist|June 4, 2017
<i>BRAF</i> Mutations as Predictive Biomarker for Response to Anti-EGFR Monoclonal AntibodiesEmilie M J van Brummelen, Anthonius de Boer, Jos H Beijnen, et al.
Plos One|December 7, 2021
Touchscreen-based finger tapping: Repeatability and configuration effects on tapping performanceSoma Makai-Bölöni, Eva Thijssen, Emilie M J van Brummelen, et al.
The Oncologist|July 22, 2016
Antidrug Antibody Formation in Oncology: Clinical Relevance and ChallengesEmilie M J van Brummelen, Willeke Ros, Gertjan Wolbink, et al.
Parkinsonism & Related Disorders|April 2, 2022
Safety and pharmacokinetics of multiple dosing with inhalable apomorphine (AZ-009), and its efficacy in a randomized crossover study in Parkinson's disease patientsEva Thijssen, Jonas M den Heijer, David Puibert, et al.
Frontiers in Oncology|September 15, 2022
Integration of healthy volunteers in early phase clinical trials with immuno-oncological compoundsIgor Radanovic, Naomi Klarenbeek, Robert Rissmann, et al.
Human Vaccines & Immunotherapeutics|November 2, 2019
Prevalent levels of RSV serum neutralizing antibodies in healthy adults outside the RSV-seasonJohan L Van Der Plas, Pauline Verdijk, Emilie M J Van Brummelen, et al.
British Journal of Clinical Pharmacology|September 24, 2021
Healthy volunteers in first-in-human oncology drug development for small moleculesBegoña de Las Heras, Dalila Bouyoucef-Cherchalli, Lesley Reeve, et al.
Journal of Clinical Movement Disorders|April 14, 2020
Quantification of tremor using consumer product accelerometry is feasible in patients with essential tremor and Parkinson's disease: a comparative studyEmilie M J van Brummelen, Dimitrios Ziagkos, Wadim M I de Boon, et al.
Vaccine|July 29, 2020
First-in-human administration of a live-attenuated RSV vaccine lacking the G-protein assessing safety, tolerability, shedding and immunogenicity: a randomized controlled trialPauline Verdijk, Johan L van der Plas, Emilie M J van Brummelen, et al.
Pageof 3